company background image
NVO

Novo Nordisk NYSE:NVO Stock Report

Last Price

US$102.55

Market Cap

US$231.5b

7D

7.6%

1Y

5.8%

Updated

03 Oct, 2022

Data

Company Financials +
NVO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance5/6
Financial Health4/6
Dividends3/6

NVO Stock Overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.102.55
52 Week Highkr.122.16
52 Week Lowkr.91.51
Beta0.29
1 Month Change0.30%
3 Month Change-7.81%
1 Year Change5.79%
3 Year Change97.48%
5 Year Change108.39%
Change since IPO20,513.11%

Recent News & Updates

Oct 03

Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec

Results from the phase 3a ONWARDS 5 trial found that Novo Nordisk's (NVO) insulin icodec bested once-daily basal insulin in terms of lowering A1c. Data showed that insulin icodec led to a superior reduction in estimated A1c of –1.68%-points compared with –1.31%-points for the basal insulin. In the trial, insulin icodec was given in combination with a dosing guide app. There was no statistically significant difference in estimated rates of severe or clinically significant hypoglycemia Novo Nordisk (NVO) expects to apply for approval with regulatory authorities in US, the EU, and China in 1H 2023. Last month, the company reported results from the ONWARDS 2 trial that compared insulin icodec to Tresiba (insulin degludec).

Sep 01

Novo to buy sick cell disease drug developer Forma for over $1B

Danish drugmaker Novo Nordisk A/S (NVO) (OTCPK:NONOF) has agreed to acquire Forma Therapeutics (FMTX), a U.S.-based biotech focused on therapies for sickle cell disease (SCD), in an all-cash deal worth $1.1B in equity value, the companies announced Thursday. Per the terms, NVO will acquire all outstanding shares of FMTX’s common stock for $20 per share in cash, indicating a ~92% premium to the company’s 30-day volume-weighted average price per share. The transaction is expected to close in Q4 2022. In connection with the deal, R.A. Capital Management, L.P., which holds nearly ~19% of FMTX shares, has agreed to tender its FMTX shares in a tender offer that NVO plans to initiate for the acquisition. FMTX’s lead asset Etavopivat is undergoing a global phase 2/3 clinical trial for SCD and a phase 2 trial for transfusion-dependent SCD and thalassemia.

Aug 11

Novo Nordisk goes ex-dividend tomorrow

Novo Nordisk (NVO) declared $0.411/share dividend. Payable Aug. 23; for shareholders of record Aug. 15; ex-div Aug. 12. See NVO Dividend Scorecard, Yield Chart, & Dividend Growth.

Shareholder Returns

NVOUS PharmaceuticalsUS Market
7D7.6%1.2%1.0%
1Y5.8%4.4%-20.0%

Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: NVO exceeded the US Market which returned -23.2% over the past year.

Price Volatility

Is NVO's price volatile compared to industry and market?
NVO volatility
NVO Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NVO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192350,816Lars Jorgensenhttps://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NVO fundamental statistics
Market CapUS$231.49b
Earnings (TTM)US$6.68b
Revenue (TTM)US$20.79b

34.6x

P/E Ratio

11.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NVO income statement (TTM)
Revenuekr.157.25b
Cost of Revenuekr.25.29b
Gross Profitkr.131.97b
Other Expenseskr.81.43b
Earningskr.50.54b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 02, 2022

Earnings per share (EPS)22.33
Gross Margin83.92%
Net Profit Margin32.14%
Debt/Equity Ratio34.2%

How did NVO perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

50%

Payout Ratio